ଓଜାନିମୋଡ

ଓଜାନିମୋଡ
Clinical data
Trade names	Zeposia
Synonyms	RPC-1063
AHFS/Drugs.com	monograph
MedlinePlus	a620029
data	EU EMA: yes; US DailyMed: Ozanimod;
Pregnancy; category	AU: D ; ;
Routes of; administration	By mouth
Legal status
Legal status	AU: S4 (Prescription only) ; US: ℞-only ; EU: Rx-only ;
Pharmacokinetic data
Elimination half-life	19 hours
Identifiers
	IUPAC name 5-(3-{(1S)-1-[(2-Hydroxyethyl)amino]-2,3-dihydro-1H-inden-4-yl}-1,2,4-oxadiazol-5-yl)-2-isopropoxybenzonitrile;
ECHA InfoCard	100.247.081
Chemical and physical data
Formula	C23H24N4O3
Molar mass	୪୦୪.୪୭ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)Oc1ccc(cc1C#N)c2nc(no2)c3cccc4c3CC[C@@H]4NCCO;
	InChI InChI=1S/C23H24N4O3/c1-14(2)29-21-9-6-15(12-16(21)13-24)23-26-22(27-30-23)19-5-3-4-18-17(19)7-8-20(18)25-10-11-28/h3-6,9,12,14,20,25,28H,7-8,10-11H2,1-2H3/t20-/m0/s1; Key:XRVDGNKRPOAQTN-FQEVSTJZSA-N;

ଓଜାନିମୋଡ, ବେପାର ନାମ ଜେପୋସିଆ , ହେଉଛି ଏକ ଔଷଧ ଯାହା ମଲ୍ଟିପ୍ଲ ସ୍କ୍ଲେରୋସିସ ବା ଏକାଧିକ ସ୍କ୍ଲେରୋସିସ୍ (ଏମ୍ଏସ୍) ଏବଂ ଅଲସରେଟିଭ କୋଲାଇଟିସ (UC)ର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।^[୨] ^[୪] ଏମ୍ଏସ୍ ମଧ୍ୟରେ କ୍ଲିନିକାଲ୍ ଆଇସୋଲେଟେଡ ସିଣ୍ଡ୍ରୋମ, ରିଲାପସିଙ୍ଗ-ରେମିଟିଙ୍ଗ୍ ଏବଂ ସକ୍ରିୟ ଦ୍ୱିତୀୟକ ପ୍ରଗତିଶୀଳ ରୋଗ ଅନ୍ତର୍ଭୁକ୍ତ ।^[୪] ଅଲସରେଟିଭ କୋଲାଇଟିସରେ ଏହି ଔଷଧ ମଧ୍ୟମରୁ ଗମ୍ଭୀର ଅବସ୍ଥା ଥିଲେ ବ୍ୟବହୃତ ହୁଏ ।^[୪] ଏହା ପାଟିରେ ଦିଆଯାଏ ।^[୪]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଉର୍ଦ୍ଧ୍ୱ ଶ୍ୱାସନଳୀ ସଂକ୍ରମଣ, ଯକୃତ ପ୍ରଦାହ, ଛିଡା ହେବା ସହିତ ନିମ୍ନ ରକ୍ତଚାପ, ମୂତ୍ରନଳୀ ସଂକ୍ରମଣ ଏବଂ ପିଠି ଯନ୍ତ୍ରଣା ହୋଇପାରେ ।^[୪] ଅନ୍ୟାନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଅନିୟମିତ ହୃତ୍ ସ୍ପନ୍ଦନ, ଉଚ୍ଚ ରକ୍ତଚାପ ଏବଂ ମାକୁଲାର ଇଡିମା ହୋଇପାରେ ।^[୪] ଗର୍ଭଧାରଣର ୩ ମାସ ପୂର୍ବରୁ କିମ୍ବା ଗର୍ଭାଧାନ ସମୟରେ ବ୍ୟବହାର କଲେ ଶିଶୁକୁ କ୍ଷତି ପହଞ୍ଚାଇପାରେ ।^[୪] ଏହା ଏକ ସ୍ପିଙ୍ଗୋସିନ୍-1-ଫସଫେଟ୍ (S1P) ରିସେପ୍ଟର ଆଗୋନିଷ୍ଟ, ଯାହାଫଳରେ ଲିମ୍ଫୋସାଇଟ୍ ମସ୍ତିଷ୍କ ଏବଂ ମେରୁଦଣ୍ଡକୁ ଯିବା ବନ୍ଦ ହୋଇଯାଏ ।^[୨] ^[୪]

୨୦୨୦ ମସିହାରେ ଆମେରିକା, ୟୁରୋପ ଏବଂ ଅଷ୍ଟ୍ରେଲିଆରେ ଚିକିତ୍ସା ପାଇଁ ଓଜାନିମୋଡ ଅନୁମୋଦିତ ହୋଇଥିଲା ।^[୨] ^[୪] ^[୫] ଯୁକ୍ତରାଜ୍ୟରେ ୪ ସପ୍ତାହର ଔଷଧ ଖର୍ଚ୍ଚ ୨୦୨୧ ସୁଦ୍ଧା ୧୪୦୦ ପାଉଣ୍ଡ ଥିଲା ।^[୬] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ରାଶିର ମୂଲ୍ୟ ପ୍ରାୟ ୭୨୦୦ ଡଲାର ଥିଲା ।^[୭]

ଆଧାର ସମ୍ପାଦନା

↑ ^୧.୦ ^୧.୧ "Zeposia Australian Prescription Medicine Decision Summary". Therapeutic Goods Administration (TGA). 27 July 2020. Archived from the original on 13 August 2020. Retrieved 16 August 2020.
↑ ^୨.୦ ^୨.୧ ^୨.୨ ^୨.୩ "Zeposia EPAR". European Medicines Agency. 26 March 2020. Archived from the original on 25 October 2020. Retrieved 17 August 2020.
↑ "Zeposia (ozanimod) capsules, for oral use" (PDF). Celgene Corporation. 25 March 2020. Archived (PDF) from the original on 26 March 2020. Retrieved 26 March 2020.
↑ ^୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ ^୪.୪ ^୪.୫ ^୪.୬ ^୪.୭ ^୪.୮ "DailyMed - ZEPOSIA- ozanimod hydrochloride capsule ZEPOSIA 7-DAY STARTER PACK- ozanimod hydrochloride kit ZEPOSIA STARTER KIT- ozanimod hydrochloride kit". dailymed.nlm.nih.gov. Archived from the original on 10 November 2021. Retrieved 10 November 2021.
↑ Australian Public Assessment Report: Ozanimod hydrochloride (Report). 25 November 2020. Archived from the original on 4 June 2021. https://web.archive.org/web/20210604060949/https://www.tga.gov.au/sites/default/files/auspar-ozanimod-hydrochloride-201125.pdf. Retrieved 4 June 2021.
↑ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 902. ISBN 978-0857114105.
↑ "Zeposia Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Retrieved 10 November 2021.

[Zeposia_APMDS-1] ୧.୦ ^୧.୧ "Zeposia Australian Prescription Medicine Decision Summary". Therapeutic Goods Administration (TGA). 27 July 2020. Archived from the original on 13 August 2020. Retrieved 16 August 2020.

[EPAR2021-2] ୨.୦ ^୨.୧ ^୨.୨ ^୨.୩ "Zeposia EPAR". European Medicines Agency. 26 March 2020. Archived from the original on 25 October 2020. Retrieved 17 August 2020.

[Zeposia_FDA_label-3] "Zeposia (ozanimod) capsules, for oral use" (PDF). Celgene Corporation. 25 March 2020. Archived (PDF) from the original on 26 March 2020. Retrieved 26 March 2020.

[PI2021-4] ୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ ^୪.୪ ^୪.୫ ^୪.୬ ^୪.୭ ^୪.୮ "DailyMed - ZEPOSIA- ozanimod hydrochloride capsule ZEPOSIA 7-DAY STARTER PACK- ozanimod hydrochloride kit ZEPOSIA STARTER KIT- ozanimod hydrochloride kit". dailymed.nlm.nih.gov. Archived from the original on 10 November 2021. Retrieved 10 November 2021.

[Au2021-5] Australian Public Assessment Report: Ozanimod hydrochloride (Report). 25 November 2020. Archived from the original on 4 June 2021. https://web.archive.org/web/20210604060949/https://www.tga.gov.au/sites/default/files/auspar-ozanimod-hydrochloride-201125.pdf. Retrieved 4 June 2021.

[BNF81-6] BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 902. ISBN 978-0857114105.

[7] "Zeposia Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Retrieved 10 November 2021.

[୨]

[୪]

[୧]

[୩]

[୫]

[୬]

[୭]